Jonas Salk

Jonas Edward Salk was born on October 28, 1914, in New York City, the eldest of three sons of Daniel and Dora Salk, Jewish immigrants of Eastern European origin who had little formal schooling themselves ^[1]. The family lived first in East Harlem and later in the Bronx, and Salk grew up in modest circumstances during years when New York's crowded neighborhoods knew infectious disease at close range. The influenza pandemic of 1918 and the recurring summer polio outbreaks of his childhood formed part of the background of his early world.

Salk was a serious, bookish child who, by his own later account, was more interested in ideas than in games. At twelve he entered Townsend Harris High School, a selective public school for gifted students that compressed four years of study into three. From there he went on to the City College of New York, an institution then famous for educating the ambitious children of immigrants at no tuition cost ^[1]. He enrolled intending to study law, but chemistry and the sciences pulled him in another direction, and he graduated in 1934 with a bachelor of science degree at the age of nineteen.

He entered the New York University School of Medicine the same year. Unusually for a medical student of his era, Salk was drawn less to treating individual patients than to the broader question of how disease could be prevented across whole populations. He took a year out of the standard curriculum to study biochemistry, and during his training he began working with Thomas Francis Jr., a bacteriologist investigating influenza viruses. That association would shape the rest of his career ^[2].

Salk received his medical degree in 1939 and completed an internship at Mount Sinai Hospital in New York, where colleagues remembered him as an exceptional clinician despite his research ambitions ^[2]. In 1942 he moved to the University of Michigan on a research fellowship to rejoin Thomas Francis, who now headed the epidemiology department of the new School of Public Health. With the United States at war, the two men worked under army sponsorship to develop influenza vaccines for the military. The project used killed, or inactivated, virus to provoke immunity without causing infection, a technique many researchers then doubted could work for viral diseases. The influenza vaccine they helped develop was field tested on army recipients and proved protective ^[3].

The Michigan years gave Salk practical command of the methods he would later apply to polio: growing viruses, inactivating them with formalin, and measuring antibody responses in vaccinated subjects. In 1947 he accepted an offer from the University of Pittsburgh School of Medicine to direct its Virus Research Laboratory. The facilities were cramped and the program small, but the post gave him independence for the first time ^[1].

Funding soon arrived from the National Foundation for Infantile Paralysis, the charity founded in 1938 with the backing of President Franklin D. Roosevelt, himself paralyzed by a disease then diagnosed as polio. The foundation, whose March of Dimes campaign made it one of the best financed philanthropies in America, recruited Salk for the painstaking work of typing poliovirus strains. The typing program confirmed that three distinct types of poliovirus existed, which meant any effective vaccine would need to protect against all three ^[4]. The work was tedious, but it positioned Salk, his laboratory, and his funders for the larger effort to come.

Poliomyelitis in mid-century America was a source of genuine public dread. Epidemics arrived each summer, closing pools and theaters, and the worst year on record, 1952, saw nearly 58,000 reported cases in the United States, with thousands of deaths and many more children left paralyzed ^[4]. A crucial scientific advance came in 1949, when John Enders, Thomas Weller, and Frederick Robbins at Harvard showed that poliovirus could be grown in cultures of non-nervous human tissue, work that earned them the 1954 Nobel Prize and made large-scale vaccine production feasible ^[3].

Salk built on that breakthrough. His approach, consistent with his influenza work, was a vaccine of poliovirus killed with formaldehyde: incapable of causing disease, he argued, yet still able to trigger protective antibodies. Prominent virologists, most notably Albert Sabin, insisted that only a live attenuated virus could give durable immunity, and the disagreement between the two men became one of the sharpest rivalries in modern medicine ^[5]. Salk pressed ahead. After tests in monkeys, he began cautious human trials in 1952 at institutions near Pittsburgh, including children who had already recovered from polio, and found the vaccine raised antibody levels safely ^[1].

The decisive test came in 1954, when the National Foundation organized a national field trial directed by Salk's former mentor Thomas Francis. Roughly 1.8 million children, remembered as the Polio Pioneers, took part in the largest medical experiment yet conducted ^[4]. On April 12, 1955, at the University of Michigan, Francis announced the verdict: the vaccine was safe, potent, and effective. The date, the tenth anniversary of Roosevelt's death, added to the sense of national occasion. Church bells rang, and Salk became a celebrity overnight. Asked on television by Edward R. Murrow who owned the patent on the vaccine, Salk replied that the people did, adding, could you patent the sun ^[1]. Weeks later, the so-called Cutter incident, in which one manufacturer released batches containing live virus that caused about 200 cases of paralytic polio, forced tighter federal safety standards but did not derail the immunization campaign ^[6].

Salk married Donna Lindsay, a psychology graduate and social worker, in 1939, the day after he received his medical degree ^[1]. The couple had three sons, Peter, Darrell, and Jonathan, all of whom became physicians; Peter Salk later led the Jonas Salk Legacy Foundation and taught at the University of Pittsburgh. The marriage ended in divorce in 1968. In 1970 Salk married the French painter Françoise Gilot, widely known for her earlier decade-long relationship with Pablo Picasso and for her memoir about those years ^[7].

Fame sat awkwardly on Salk. The public adored him, and mail arrived by the sackful after 1955, but many fellow scientists were cooler. He was never elected to the National Academy of Sciences, a snub often attributed to resentment of his celebrity and to the view among some virologists that his vaccine rested chiefly on the discoveries of others ^[5]. Salk himself said the attention isolated him. Colleagues described a reserved, driven man with a philosophical bent who preferred writing and reflection to the rounds of scientific society.

He received honors from outside the academy in abundance, including a Congressional Gold Medal in 1955 and the Presidential Medal of Freedom in 1977, awarded by President Jimmy Carter ^[2].

In the early 1960s Salk turned his energy toward building an institution rather than another vaccine. With backing from the National Foundation and a gift of land from the city of San Diego, he founded the Salk Institute for Biological Studies in La Jolla, California, which opened its laboratories in 1963 ^[8]. He recruited the architect Louis Kahn to design the campus, and the result, twin rows of concrete laboratory towers facing a travertine plaza open to the Pacific, is regarded as one of the great works of twentieth century architecture. Salk wanted a place where biologists could work alongside humanists, telling Kahn he hoped to create a facility fit to invite Picasso to visit.

At the institute Salk continued research on autoimmune disease, multiple sclerosis, and cancer, and he published several books of reflective, philosophical writing, among them Man Unfolding (1972) and The Survival of the Wisest (1973), which explored human evolution and the responsibilities of science ^[2]. Meanwhile, in the United States, Sabin's live oral vaccine largely displaced Salk's injected version during the 1960s because it was cheaper and easier to administer, though improved inactivated vaccine of the Salk type returned to exclusive use in the American immunization schedule in 2000 after the oral vaccine's rare paralytic side effects became the country's only remaining source of polio ^[6].

In his final decade Salk took on one more urgent problem. From the mid 1980s he directed efforts to develop an immunotherapeutic vaccine against HIV, working through the Immune Response Corporation, which he co-founded. The product, Remune, did not achieve success in trials, but Salk pursued the work until the end of his life ^[8]. He died of heart failure in La Jolla on June 23, 1995, at the age of eighty ^[2].

Any account of who was Jonas Salk begins with a number: in the United States, reported polio cases fell from tens of thousands a year in the early 1950s to a few hundred within a decade of the 1955 announcement, and domestic transmission of wild poliovirus ended entirely by 1979 ^[6]. The Global Polio Eradication Initiative, launched in 1988, has since driven wild polio from all but a handful of districts on earth using both the Sabin oral vaccine and modern versions of Salk's inactivated vaccine, which remains essential to the endgame strategy ^[4]. Few medical interventions have removed so much fear from ordinary family life so quickly.

Jonas Salk facts often circulate around his refusal to profit from the vaccine, and the story has hardened into legend, though historians note the foundation had also concluded the vaccine was likely unpatentable. Either way, his decision not to seek personal ownership fixed his public image as a scientist working for the common good ^[5]. The scientific establishment's ambivalence toward him has softened with time, and his method, the killed-virus vaccine once dismissed as a dead end, underlies vaccines against influenza, hepatitis A, and rabies in use today.

Among Jonas Salk achievements, the institute that carries his name may prove the most durable. The Salk Institute has housed multiple Nobel laureates and remains a leading center of research in neuroscience, genetics, and plant biology ^[8]. Streets, schools, and hospitals across the United States bear his name, and the anniversary of the 1955 announcement is still marked each April. Any full Jonas Salk biography ends where his own stated ambition began: with the idea that the reward for good work is the chance to do more of it.